Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 9.7% in March

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 283,100 shares, a drop of 9.7% from the March 15th total of 313,400 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is presently 0.1 days.

Avenue Therapeutics Price Performance

ATXI stock opened at $0.13 on Wednesday. The stock has a market capitalization of $5.82 million, a price-to-earnings ratio of -0.10 and a beta of -0.24. The business’s fifty day moving average price is $0.15 and its two-hundred day moving average price is $0.22. Avenue Therapeutics has a fifty-two week low of $0.11 and a fifty-two week high of $1.28.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Monday, March 18th. The company reported $0.56 earnings per share for the quarter.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Avenue Therapeutics during the 1st quarter worth $28,000. Renaissance Technologies LLC bought a new position in shares of Avenue Therapeutics in the second quarter worth $34,000. State Street Corp bought a new position in shares of Avenue Therapeutics in the first quarter worth $36,000. Geode Capital Management LLC increased its position in shares of Avenue Therapeutics by 359.9% in the second quarter. Geode Capital Management LLC now owns 52,571 shares of the company’s stock worth $60,000 after purchasing an additional 41,141 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Avenue Therapeutics in the third quarter worth $145,000. Institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.